ROS1 and non-small cell lung carcinoma: Thus, the identification of therapeutically relevant gene fusions (ALK, ROS1, RET and NTRK) and MET exon 14 skipping mutations is pivotal in choosing correct management of advanced-stage NSCLC [3,6].